Gallium-68-THP PSMA

Drug Profile

Gallium-68-THP PSMA

Alternative Names: (68)Ga-THP-PSMA; 68Ga-THP-PSMA; [68Ga]THP-PSMA PET/CT; [68Ga]Tris(hydroxypyridinone)(THP)-PSMA; Ga-68-THP-PSMA; Gallium-68 tris-hydroxypyridinone prostate specific membrane antigen; THG-001

Latest Information Update: 29 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kings College London
  • Developer Peter MacCallum Cancer Centre; Theragnostics
  • Class Diagnostic agents; Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Prostate cancer

Most Recent Events

  • 25 Jun 2018 Phase-II clinical trials in Prostate cancer (Diagnosis) in United Kingdom (IV)
  • 01 Feb 2017 Peter MacCallum Cancer Centre and Theragnostics complete a phase I trial in Prostate cancer (Diagnosis, In adults, In the elderly) in Australia (IV) (ACTRN12615001324505)
  • 01 Nov 2016 Interim adverse events and pharmacodynamics data from a phase I trial in Prostate cancer (Diagnosis) released by Theragnostics and Peter MacCallum Cancer Centre
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top